Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
FGF8 Biologics Sequence Review Report 2026: Fibroblast growth factor 8 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FGF8 Biologics Sequence Review Report 2026: Fibroblast growth factor 8 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FGF23 Biologics Sequence Review Report 2026: Fibroblast growth factor 23 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FGF23 Biologics Sequence Review Report 2026: Fibroblast growth factor 23 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF23 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FGF22 Biologics Sequence Review Report 2026: Fibroblast growth factor 22 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FGF22 Biologics Sequence Review Report 2026: Fibroblast growth factor 22 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF22 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FGF20 Biologics Sequence Review Report 2026: Fibroblast growth factor 20 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FGF20 Biologics Sequence Review Report 2026: Fibroblast growth factor 20 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF20 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FGF14 Biologics Sequence Review Report 2026: Fibroblast growth factor 14 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FGF14 Biologics Sequence Review Report 2026: Fibroblast growth factor 14 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF14 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FGF13 Biologics Sequence Review Report 2026: Fibroblast growth factor 13 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FGF13 Biologics Sequence Review Report 2026: Fibroblast growth factor 13 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF13 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FGF12 Biologics Sequence Review Report 2026: Fibroblast growth factor 12 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FGF12 Biologics Sequence Review Report 2026: Fibroblast growth factor 12 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF12 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FGF11 Biologics Sequence Review Report 2026: Fibroblast growth factor 11 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FGF11 Biologics Sequence Review Report 2026: Fibroblast growth factor 11 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF11 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
EFNB3 Biologics Sequence Review Report 2026: Ephrin-B3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
EFNB3 Biologics Sequence Review Report 2026: Ephrin-B3 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of EFNB3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
EFNB2 Biologics Sequence Review Report 2026: Ephrin-B2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
EFNB2 Biologics Sequence Review Report 2026: Ephrin-B2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of EFNB2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
EFNB1 Biologics Sequence Review Report 2026: Ephrin-B1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
EFNB1 Biologics Sequence Review Report 2026: Ephrin-B1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of EFNB1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
EFNA5 Biologics Sequence Review Report 2026: Ephrin-A5 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
EFNA5 Biologics Sequence Review Report 2026: Ephrin-A5 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of EFNA5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →